ArticleInternational braz j urol : official journal of the Brazilian Society of Urology
Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Blood count-derived inflammatory markers predict time to Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer.Archives of medical science : AMS · 2026Article
- Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Assessment of quality of life in patients undergoing hyperthermic intravesical chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24).International urology and nephrology · 2025Article
- Diagnostic value of preoperative computed tomography-urography combined with inflammatory markers in predicting lymph node metastasis in patients undergoing radical cystectomy.Bladder (San Francisco, Calif.) · 2025Article
- Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.The Pan African medical journal · 2023Article
- Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.International journal of urology : official journal of the Japanese Urological Association · 2022Review
- Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.Cancer immunology, immunotherapy : CII · 2022Article
- Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).ClinicoEconomics and outcomes research : CEOR · 2022Review
- Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.Cancer science · 2021Article
- Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure.Arab journal of urology · 2021Article
- Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer.Frontiers in oncology · 2021Article
- SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?Urologia internationalis · 2020Review
- Role of Systemic Inflammatory Response Markers in Urothelial Carcinoma.Frontiers in oncology · 2020Review
- Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.Central European journal of urology · 2020Article
- Preoperative pyuria predicts the presence of high-grade bladder carcinoma in patients with bladder tumors.Central European journal of urology · 2020Article
- Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors.Journal of oncology · 2019Review
- Proteomic research and diagnosis in bladder cancer: state of the art review.International braz j urol : official journal of the Brazilian Society of UrologyReview
- Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review.International braz j urol : official journal of the Brazilian Society of UrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor for response of high risk non muscle invasive bladder cancer (HRNMIBC) treated with BCG therapy. MATERIALS AND
methodsBetween March 2010 and February 2014 in a tertiary center 100 consecutive patients with newly diagnosed HRNMIBC were retrospectively analyzed. Patients were divided according to NLR value: 46 patients with NLR value less than 3 (NLR < 3 group), and 54 patients with NLR value more than 3 (NLR ≥ 3 group). At the end of follow-up 52 patients were high grade disease free (BCG-responder group) and 48 patients underwent radical cystectomy for high grade recurrence or progression to muscle invasive disease (BCG non-responder group). The average follow-up was 60 months.
interventionanalysis and correlation of preoperative NLR value with response to BCG in terms of recurrence and progression.
resultsThe optimal cut-off for NLR was ≥ 3 according to the receiver operating characteristics analysis (AUC 0.760, 95% CI, 0.669-0.850). Mean NLR value was 3.65 ± 1.16 in BCG non-responder group and 2.61 ± 0.77 in BCG responder group (p = 0.01). NLR correlated with recurrence (r = 0.55, p = 0.01) and progression risk scores (r = 0.49, p = 0.01). In multivariate analysis, NLR (p = 0.02) and EORTC recurrence risk groups (p = 0.01) were associated to the primary endpoint. The log-rank test showed statistically significant difference between NLR < 3 and NLR ≥ 3 curves (p < 0.05).
conclusionsNLR value preoperatively evaluated could be a useful tool to predict BCG response of HRNMIBC. These results could lead to the development of prospective studies to assess the real prognostic value of NLR in HRNMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.